• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • China post-market surveillance regulatory research meeting – 2022 summary report

China post-market surveillance regulatory research meeting – 2022 summary report

China post-market surveillance
Thursday, 29 December 2022 / Published in Medical Device, News, NMPA Registration in China

China post-market surveillance regulatory research meeting – 2022 summary report

China post-market surveillance regulations for medical devices in 2022 were being reviewed in a meeting carried out by the National Medical Products Administration (NMPA) on December 8, 2022.

Work report on laws and regulations in different provinces and cities

During the meeting, the provincial medical products administration units provided a summary report on each respective regulatory research work carried out for supervision of medical device production, operation, network sales, sampling inspection, adverse event monitoring and case investigation in 2022:

  • The Medical Products Administration of Zhejiang Province took the lead in drafting documents such as “Opinions on Strengthening the Collaborative Supervision of Cross-Regional Commissioned Production of Medical Devices” to continuously enrich the production supervision system and promote the implementation of responsibilities of all parties.
  • The Medical Products Administration of Jilin Province took the lead in completing the research on third-party logistics of medical devices, and provided support for the release of the “Appendix of Medical Device Operation Quality Management Standards: Quality Management of Enterprises Specializing in Medical Device Transportation and Storage Services”.
  • The Medical Products Administration of Shandong Province conducts research on the investigation, evaluation and recall of products that do not meet the requirements of sampling inspection, improves the disposal procedures of technical means of supervision and sampling inspection, and promotes the improvement of work efficiency.
  • The Medical Products Administration of Peking enriched the basis of adverse event monitoring and evaluation from the aspects of regulations, technology and cases.
  • The Medical Products Administration of Guangdong Province investigated the implementation of laws and regulations of third-party platform enterprises and online sales enterprises of medical device online trading services, and put forward relevant suggestions on the difficulties, pain points and obstacles of grassroots supervision.
  • The Medical Products Administration of Hunan Province investigated the implementation of rules, norms and systems in the use process and put forward suggestions for revision and improvement.
  • The Medical Products Administration of Jiangsu Province compared the new models such as cross-regional commissioned production under the full implementation of the registrant system, and studied how to carry out supervision and law enforcement more effectively in practice.

Further information

Click here to read the full announcement of the meeting held to review the medical device post-market surveillance regulations in 2022.

If you would like to learn more about the China post-market surveillance requirements or how we can support you to comply with the requirements for selling medical devices in China, please contact us.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

CMDE Compares EU and China Risk Management
China medical device standards management 2022
China medical device standards management 2022 annual report issued
china class I medical device filing
China class I medical device filing clarification

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • laser therapy devices

    Clinical evaluation of laser therapy devices – New guidelines issued

    Clinical evaluation of laser therapy devices ha...
  • dental implant system

    Clinical evaluation of dental implant systems in China – New guidelines issued

    Clinical evaluation of dental implant system ha...
  • China Medical Device Webinar

    China Medical Device Webinar with AdvaMed Accel for U.S. exporters

    The China Medical Device Webinar will be featur...
  • webinar_medical-device-market-authorisation

    Cisema presenting at FORUM Institut: Medical device marketing authorisation for advanced – Masterclass China

    Cisema is delighted to hold a Masterclass with ...
  • generative AI services

    China’s generative AI interim measures now in effect

    China’s generative AI interim measures fo...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP